References:
1. Crombie JL, LaCasce AS. Epstein Barr Virus Associated B-Cell Lymphomas and Iatrogenic Lymphoproliferative Disorders. Front Oncol 2019;9:109.
2. Fauci AS, Haynes BF, Costa J, Katz P, Wolff SM. Lymphomatoid Granulomatosis. Prospective clinical and therapeutic experience over 10 years. N Engl J Med 1982;306:68-74.
3. Katzenstein AL, Doxtader E, Narendra S. Lymphomatoid granulomatosis: insights gained over 4 decades. Am J Surg Pathol 2010;34:e35-48.
4. Liebow AA, Carrington CR, Friedman PJ. Lymphomatoid granulomatosis. Hum Pathol 1972;3:457-558.
5. Melani C, Jaffe ES, Wilson WH. Pathobiology and treatment of lymphomatoid granulomatosis, a rare EBV-driven disorder. Blood 2020;135:1344-52.
6. Wilson WH, Kingma DW, Raffeld M, Wittes RE, Jaffe ES. Association of lymphomatoid granulomatosis with Epstein-Barr viral infection of B lymphocytes and response to interferon-alpha 2b. Blood 1996;87:4531-7.
7. Sebire NJ, Haselden S, Malone M, Davies EG, Ramsay AD. Isolated EBV lymphoproliferative disease in a child with Wiskott-Aldrich syndrome manifesting as cutaneous lymphomatoid granulomatosis and responsive to anti-CD20 immunotherapy. J Clin Pathol 2003;56:555-7.
8. Benouaich-Amiel A Y-KS, Fichman S, Siegal T. Lymphomatoid granulomatosis of the central nervous system successfully treated with corticosteroid alone: a case report and review of the literature. Neurosurg Cases Rev 2018;1:009.
9. Lucantoni C, De Bonis P, Doglietto F, et al. Primary cerebral lymphomatoid granulomatosis: report of four cases and literature review. J Neurooncol 2009;94:235-42.
10. Zaidi A, Kampalath B, Peltier WL, Vesole DH. Successful treatment of systemic and central nervous system lymphomatoid granulomatosis with rituximab. Leuk Lymphoma 2004;45:777-80.
11. Knoops L, Haas R, de Kemp S, et al. In vivo p53 response and immune reaction underlie highly effective low-dose radiotherapy in follicular lymphoma. Blood 2007;110:1116-22.
12. Skvortsova I, Skvortsov S, Popper BA, et al. Rituximab enhances radiation-triggered apoptosis in non-Hodgkin’s lymphoma cells via caspase-dependent and - independent mechanisms. J Radiat Res 2006;47:183-96.
13. Witzens-Harig M, Hensel M, Unterhalt M, Herfarth K. Treatment of limited stage follicular lymphoma with Rituximab immunotherapy and involved field radiotherapy in a prospective multicenter Phase II trial-MIR trial. BMC Cancer 2011;11:87.
14. Brocklehurst S DN, Shah JL, Rizvi S, Ramakrishnan Geethakumari P, Kumar K. Combined Modality Low-Dose Radiation Therapy (2 Gy x 2) and Single-Agent Rituximab Immunotherapy in the Treatment of Indolent Non-Hodgkin Lymphoma. Blood 2019;134:5262.
15. Bollard CM, Gottschalk S, Torrano V, et al. Sustained complete responses in patients with lymphoma receiving autologous cytotoxic T lymphocytes targeting Epstein-Barr virus latent membrane proteins. J Clin Oncol 2014;32:798-808.